Preimplantation genetic screening (PGS) through 24-chromosome aneuploidy screening of day 3 embryos in advanced maternal aged patients: a prospective randomised controlled trial

INTERVENTION: 1. Control group: ICSI procedure, day 3 zona pellucida laser assisted drilling without blastomere biopsy and Preimplantaion Genetic Screening (PGS), day 5 up to double embryo transfer . 2. Study group: ICSI, one‐cell embryo biopsy on day 3 and Preimplantation Genetic Screening with array‐CGH, day 5 up to double embryo transfer. Embryos with dubious results will be reanalysed by trofoblast biopsy and array‐CGH. All available supenumerary viable embryos will be cryopreserved by vitrification procedure in both groups. CONDITION: Infertility ; Pregnancy and Childbirth ; Female infertility PRIMARY OUTCOME: Ongoing pregnancy rate per embryo transfer (defined as the ratio between the number of ; ongoing prergnancy greater than 20 weeks gestation and the number of embryo transfer performed) SECONDARY OUTCOME: 1. Embryo transfer rate per started cycle; 2. Ongoing implantation rate; 3. Miscarriage rate; 4. Multiple pregnancy rate; 5. Ongoing pregnancy rate per started cycle INCLUSION CRITERIA: 1. Female patients aged between 36 and 43 years undergoing an in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) attempt at the GENERA centre for Reproductive Medicine in Rome 2. History of less than 3 consecutive miscarriages and no more than 2 failed IVF/ICSI cycles 3. Greater than or equal to 6 metaphase II (MII) oocytes retrieved 4. Signed consent form